V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis

Blood

Volumn 107, Issue 5, 2006, Pages 2098-2100

  Campbell, Peter J ^b   Griesshammer, Martin ^b   Döhner, Konstanze ^b   Döhner, Hartmut ^b   Kusec, Rajko ^b   Hasselbalch, Hans C ^b   Larsen, Thomas Stauffer ^b   Pallisgaard, Niels ^b   Giraudier, Stéphane ^b   Le Bousse Kerdilès, Marie Caroline ^b   Desterke, Christophe ^b   Guerton, Bernadette ^b   Dupriez, Brigitte ^b   Bordessoule, Dominique ^b   Fenaux, Pierre ^b   Kiladjian, Jean Jacques ^b   Viallard, Jean François ^b   Brière, Jean ^b   Harrison, Claire N ^b   Green, Anthony R ^b   Reilly, John T ^a   more..

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 2;

ADULT; ARTICLE; BLOOD TRANSFUSION; CANCER DIAGNOSIS; CANCER SURVIVAL; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE MUTATION; GENETIC ASSOCIATION; GENOTYPE; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MYELOID METAPLASIA; OUTCOMES RESEARCH; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SURVIVAL RATE;

EID: 33344471678     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-08-3395     Document Type: Article

References (9)

1. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054-1061.
2. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434:1144-1148.
3. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387-397.
4. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779-1790.
5. Barosi G, Ambrosetti A, Finelli C, et al. The Italian Consensus Conference on Diagnostic Criteria for Myelofibrosis with Myeloid Metaplasia. Br J Haematol. 1999;104:730-737.
6. Dupriez B, Morel P, Demory JL, et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood. 1996;88:1013-1018.
7. Campbell PJ, Scott LM, Buck G, et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet. 2005;366:1945-1953.
8. Cox DR. Regression models and life tables (with discussion). J Royal Stat Soc Series B. 1972;34:187-220.
9. Brawley OW, Kramer BS. Cancer screening in theory and in practice. J Clin Oncol. 2005;23:293-300.